Microbial Tryptamine as a Causative Cofactor of Incurable Cell Death Diseases of Unknown Etiology
Academic Press Inc (Verlag)
978-0-443-27642-2 (ISBN)
- Noch nicht erschienen (ca. Oktober 2026)
- Versandkostenfrei
- Auch auf Rechnung
- Artikel merken
Additionally, the latest advances in treatment and prevention are considered. It then provides a critical analysis of expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration, alongside an evaluation of current funding and market analysis. Following this, the author delves into research-related issues that may hinder biomedical progress, such as competition, plagiarism, and retractions of funded peer-reviewed articles. Collaboration between researchers and medical doctors is also examined. The book concludes with the author’s own personal narrative and recommendations, emphasizing the need for open discussions to drive urgent changes in biomedical research funding and review processes.
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.
Part 1. Microbial tryptamine in diseases
1. Introduction: Contamination of food products with microbes producing cytotoxic tryptamine that induces gut dysbiosis
2. Differential abundance of tryptamine and related human gut microbial NQR sequence (ADAS) in cancers of gastrointestinal (GI) system and neurodegenerative diseases, spending budgets
3. Tryptamine in cell and organ transplantation
4. The roles of the diet and environment in the start and progression of diseases
5. Tryptamine-induced diseases: Future of biomedicine in saving lives by testing, preventing and treating the preventable/avoidable and modifiable medical conditions
Part 2. Expenditure and research funding
6. Expenditure on diseases related to tryptamine-induced cell toxicity and neurodegeneration
7. Funding of research projects and market analysis for diseases related to tryptamine
Part 3. Research-related issues interfering with the progress in the biomedical project
8. Competition, plagiarism and profit-driven motives in science
9. Massive retractions of funded articles is a symptom of serious failures in research funding
10. How do biology doctors and medical doctors - clinicians collaborate?
Part 4. A personal narrative and conclusive remarks
11. About the Author
12. Conclusions
| Erscheint lt. Verlag | 1.10.2026 |
|---|---|
| Verlagsort | San Diego |
| Sprache | englisch |
| Maße | 191 x 235 mm |
| Gewicht | 450 g |
| Themenwelt | Naturwissenschaften ► Biologie ► Genetik / Molekularbiologie |
| ISBN-10 | 0-443-27642-0 / 0443276420 |
| ISBN-13 | 978-0-443-27642-2 / 9780443276422 |
| Zustand | Neuware |
| Informationen gemäß Produktsicherheitsverordnung (GPSR) | |
| Haben Sie eine Frage zum Produkt? |
aus dem Bereich